CD117 immunoreactivity in atypical fibroxanthoma

American Journal of Dermatopathology

Volumn 30, Issue 1, 2008, Pages 34-36

  Mathew, Rahel A ^a   Schlauder, Scott M ^b,c   Calder, Kenneth B ^a   Morgan, Michael B ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Atypical fibroxanthoma; c kit; CD117

Indexed keywords

STEM CELL FACTOR RECEPTOR;

AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; FIBROXANTHOMA; HEAD AND NECK TUMOR; HUMAN; IMMUNOREACTIVITY; MALE; MAST CELL; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 38549130803     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31815b8ed5     Document Type: Article

References (24)

1. Longacre TA, Smoller BR, Rouse RV. Atypical fibroxanthoma of the skin: multiple immunohistologic profiles. Am J Surg Pathol. 1993;17:1199-209.
2. Worrell JT, Ansari MQ, Ansari SJ, et al. Atypical fibroxanthoma: DNA ploidy analysis of 14 cases with possible histogenetic implications. J Cutan Pathol. 1993;20:211-5.
3. Koch CA, Gimm O, Vortmeyer AO, et al. Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy? Ann N Y Acad Sci. 2006;1073:517-526.
4. Pelosi G, Barisella M, Pasini F, et al. CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients. Mod Pathol. 2004;17:711-721.
5. Ferrari L, Della Torre S, Collini P, et al. Kit protein (CD117) and proliferation index (Ki-67) evaluation in well and poorly differentiated neuroendocrine tumors. Tumori. 2006;92:531-535.
6. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary results. Invest New Drugs. 1999;17:259-269.
7. Seidal T, Edvardsson H. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology. 1999;34:416-424.
8. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340-4346.
9. Murali R, Palfreeman S. Clear cell atypical fibroxanthoma-report of a case with review of the literature. J Cutan Pathol. 2006;33:343-348.
10. Crowson AN, Carlson-Sweet K, Macinnis C, et al. Clear cell atypical fibroxanthoma: a clinicopathologic study. J Cutan Pathol. 2002;29:374.
11. Dettrick A, Strutton G. Atypical fibroxanthoma with perineural or intraneural invasion: report of two cases. J Cutan Pathol. 2006;33:318-322.
12. Weiss SW, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors. 4th ed. St Louis: Mosby; 2001.
13. Helwig EB, May D. Atypical fibroxanthoma of the skin with metastasis. Cancer. 1986;57:368.
14. Kargi E, Gungor E, Verdi CM, et al. Atypical fibroxanthoma and metastasis to the lung [letter]. Plast Reconstr Surg. 2003;111:1760.
15. Silvis NG, Swanson PE, Manivel JC, et al. Spindle cell and pleomorphic neoplasms of the skin: a clinicopathologic and immunohistochemical study of 30 cases with emphasis on 'atypical fibroxanthoma.' Am J Surg Pathol. 1988;10:9.
16. Cooper JZ Newman SR, Scott GA, et al. Metastasizing atypical fibroxanthoma (cutaneous malignant histiocytoma): report of five cases. Dermatol Surg. 2005;31:221-225.
17. Pignon JM. C-kit mutations and mast cell disorders. A model of activating mutations of growth factor receptors. Hematol Cell Therapy. 1997;39:114-116.
18. Swick BL, Ravdel L, Fitzpatrick JE, et al. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene- implications for treatment with imatinib mesylate. J Cutan Pathol. 2007;34:324-329.
19. Horie M, Hatamochi A, Yamazaki S, et al. A case of cutaneous leiomyosarcoma with overexpression of KIT: do CD117 (KIT)-positive primary gastrointestinal stromal tumours of the skin exist? Br J Dermatol. 2006;154:1013-1016.
20. Weedon D, Williamson RM, Mizra B. CD10 a useful marker in atypical fibroxanthoma. Am J Derm Pathol. 2005;27:181.
21. Monteagudo C, Calduch L, Navarro S, et al. CD99 immunoreactivity in atypical fibroxanthoma: a common feature of diagnostic value. Am J Clin Pathol. 2002;117:126.
22. Hartel PH, Jackson J, Ducatman BS, et al. CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker. J Cutan Pathol. 2006;33(Suppl 2):24-28.
23. Jensen K, Wilkinson B, Wines N, et al. Procollagen 1 expression in atypical fibroxanthoma and other tumors. J Cutan Pathol. 2004;31:57-61.
24. Hultgren T, DiMaio D. Immunohistochemical staining of CD10 in atypical fibroxanthomas. J Cutan Pathol. 2007;34:415-419.